120 Participants Needed

Sovilnesib for Ovarian Cancer

Recruiting at 12 trial locations
VT
Overseen ByVolastra Therapeutics, Inc.
Age: 18+
Sex: Female
Trial Phase: Phase 1
Sponsor: Volastra Therapeutics, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a randomized, phase 1b study to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of sovilnesib at different dose levels to establish the Recommended Phase 2 Dose (RP2D) of sovilnesib in subjects with high grade serous ovarian cancer (HGSOC).

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Are You a Good Fit for This Trial?

This trial is for adults over 18 with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer that's metastatic or can't be surgically removed. They should have tried platinum-based therapy but had the cancer return within 6 months or didn't respond to it at all. Participants may have had prior treatments like bevacizumab unless they're intolerant or ineligible.

Inclusion Criteria

I am fully active or can carry out light work.
I have at least one tumor that can be measured on a CT scan or MRI.
I can swallow pills without needing to change them.
See 1 more

Exclusion Criteria

I have been treated with a KIF18A inhibitor before.
My cancer has spread to my brain or spinal cord.
I have a condition that affects how my body absorbs pills.
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment Part 1

10 subjects are randomized to each of the open dose levels to generate preliminary PK, PD, safety, tolerability, and efficacy data

28-day cycles
Multiple visits as per cycle

Treatment Part 2

20-30 additional subjects are randomized to 2 or more dose levels examined in Part 1 to determine the RP2D

28-day cycles
Multiple visits as per cycle

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Sovilnesib
Trial Overview The study tests different doses of Sovilnesib to find a safe and effective level for phase 2 trials in patients with advanced ovarian cancer. It's randomized, meaning participants are put into groups by chance to receive varying doses and their responses are compared.
How Is the Trial Designed?
4Treatment groups
Experimental Treatment
Group I: Dose Level 4Experimental Treatment1 Intervention
Group II: Dose Level 3Experimental Treatment1 Intervention
Group III: Dose Level 2Experimental Treatment1 Intervention
Group IV: Dose Level 1Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Volastra Therapeutics, Inc.

Lead Sponsor

Trials
3
Recruited
310+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security